<qa>  What is the name of the biomarker listed in 1.3. To evaluate potential new breast tissue-based biomarkers including Ki-67, PCNA, ER, COX-2, aromatase, methylation of key tumor suppressor genes i.e., RAR, p16, etc, proteomic patterns in RPFNA and nipple aspirate fluid NAF, as well as NAF hormone levels, and correlate them with other risk biomarkers listed in 1. 